Clinical Trial Update: An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations. [Phase 3]

View source ↗

Summary

An open-label safety extension of SLV308 in Parkinson's disease patients with motor fluctuations, completed after the Phase 3 S308.3.002 study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SLV308

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Advanced Stage Parkinson's Disease | Phase 3 | Status: COMPLETED